Background and Aims: Histological remission [HR] is a potential treatment target in ulcerative colitis [UC]. Limited 'real world' data are available on the reliability of histological scoring when assessing minimal histological inflammation. The aim of this study was to investigate the reliability of UC histological scores in colonic biopsies showing mucosal healing [MH] and limited histological inflammation, and to compare the 'daily practice' histological assessment with expert reviews by gastrointestinal [GI] pathologists. Methods: We performed a retrospective single-centre study. Colonic biopsies from UC patients with MH [Mayo score ≤ 1] were included. All biopsies assessed in daily practice were reassessed by three blinded GI pathologists using three histological scores (Geboes score [GS], Riley score [RS], Harpaz [Gupta] Index [HGI]) and a global visual scale [GVS]. We evaluated inter-and intraobserver variation between GI pathologists and correlations between scores including the initial histological assessment using Cronbach's alpha and Spearman rho analysis. Results: In total, 270 biopsies from 39 UC patients were included. The inter-observer concordance for all histological indexes was substantial to almost perfect [GS 0.84; HGI 0.61; GVS 0.74, RS 0.91]. Correlation between the RS and GS was almost perfect [R = 0.86], but we found no correlation between the primary histological assessment and reassessment by GI pathologists. Conclusions: Current UC histological scores reliably assess limited histological inflammation in UC patients. The discrepancy between the initial histological assessment and the reassessment by dedicated GI pathologists suggests a gap between daily practice and academic expertise. This issue may limit the implementation of HR as a treatment target for UC in daily practice.
Introduction
Treatment goals for inflammatory bowel disease [IBD] have changed from assessing primarily symptom-based treatment to evaluating treatment targets that combine both patient-reported outcome [PRO] remission and endoscopic remission (mucosal healing [MH] ). 1 The advent of biologicals with positive effects on mucosal inflammation has contributed significantly to this shift. [2] [3] [4] [5] [6] MH is a well-accepted treatment target in clinical IBD trials [7] [8] [9] [10] and is associated with relevant clinical outcomes. 6, [11] [12] [13] Some clinical trials have introduced even more stringent treatment targets in IBD such as 'histological remission [HR] '. HR might be a better predictor of a more favourable disease course, in particular in ulcerative colitis [UC] . [14] [15] [16] [17] [18] However, there is no unified definition of HR, 15, 19, 20 which seems pivotal for the design and comparability of clinical trials, but also for the use of HR as a treatment target in daily practice. Several scoring indexes are available to measure histological activity in UC. Frequently used scores include the Geboes score [GS], Riley score [RS] and to a lesser extent the easy to use Harpaz [Gupta] Index [HGI] . Only limited data on the reproducibility of these scores were available until recently. [21] [22] [23] Two studies evaluating the reproducibility and reliability of these histological activity indexes showed a strong correlation between scores and good intra-observer reproducibility with moderate to good interobserver agreement. 24, 25 The greater portion of patients in both studies, however, had [mildly] active disease. Indeed, the histological item that showed the strongest intra-and inter-observer agreement was 'erosion/ulceration', a feature that correlates with active disease. In addition, the assessing pathologists were all expert gastrointestinal [GI] pathologists. This leads us to two questions. First, does this high observer agreement still hold when re-evaluating colonic biopsies with MH that were initially assessed by a general pathologist as 'HR'. Secondly, do these histological indexes, so far mainly used in clinical trials, correlate with the histological assessment in daily practice by a general pathologist? To assess these questions, we designed a study to compare the reproducibility and reliability of three histological scoring indexes [GS, RS, HGI] and one global visual score [GVS] through intra-and inter-observer agreement testing, in colonic biopsies with MH that were primarily assessed as HR in daily practice. We also investigated the correlation between histological assessment of UC biopsies in daily practice and the re-assessment by specialized GI pathologists.
Materials and Methods

Study design
We designed a retrospective single-centre study in a tertiary referral centre. This trial [ISRCTN61139227] was approved by the Ethics Committee of Radboud University Medical Centre, Nijmegen, the Netherlands.
Patients
We searched our endoscopy database to identify patients with established UC who met the inclusion criteria. 
Statistical analysis
SPSS version 22.0 and Scilab were used for the statistical analysis. We used descriptive statistics to analyse the results using counts and proportions for categorical data and means and standard deviations for continuous variables. We evaluated inter-and intra-observer variation of GI pathology experts for GS, HGI and GVS total scores in biopsies taken from endoscopically healed mucosa with Cronbach's alpha statistics, and for the 95% confidence interval we used bootstrapping and provided the percentage of agreement. We used the interpretation of kappa values as suggested by Landis 29 : 0.00 poor; 0.00-0.20 slight; 0.21-0.40 fair; 0.41-0.60 moderate; 0.61-0.80 substantial; 0.81-1.00 almost perfect. For the RS we evaluated interand intra-observer concordance between the six different items of the RS with Cronbach's alpha statistics. Where there was almost perfect inter-observer concordance, we provide the percentage of agreement, because Cronbach's alpha statistics could not reliable be used. The relationship between indexes was studied by Spearman's correlation coefficient. We compared the outcome of biopsies that are primarily assessed as 'normal' [gpHR] or 'abnormal' [gpHI] by the general pathologist, and GI pathology experts.
Results
General
We 
Endoscopy and histology scores -general pathologist vs expert GI-pathologists
The general pathologist assessed 84.8% of the rectosigmoid biopsies, endoscopically scored as Mayo 0, as gpHR; in the proximal colon biopsies this was 94.1% [ Table 2 ]. For endoscopy score Mayo 1, the general pathologist assessed 20% [2/10] of the biopsies in the rectum and sigmoid as gpHR.
The results of the re-evaluation of the Mayo 0 and 1 biopsies by expert GI-pathologists using three histological scores [GS, HGI, RS] are depicted in Table 2 . To calculate these percentages for all three GI-pathologists, we used the sum of all biopsies. The used cut-offs of the GS [<0.1, <3.1] were used in concordance with the literature. 15 
Inter-observer agreement expert GI-pathologists
For all evaluated histological scores, inter-observer concordance was higher in sections assessed as Mayo score 1 vs sections assessed as Mayo score 0 [ Table 3 and Table S4 ].
Harpaz [Gupta] index [HGI]
Overall inter-observer concordance in the HGI was substantial 
Riley score [RS]
Inter-observer concordance was determined for each separate item of the RS. The inter-observer concordance for all six items was substantial to almost perfect [ Table S4 ]. Where the evaluated sections were distinguished according to the initial assessment, inter-observer concordance was moderate to substantial for all six items in gpHR; in gpHI this was almost perfect for five out of six items, with 'crypt architectural irregularities' as the only outlier with a moderate result. When the evaluated items were divided according to Mayo score, inter-observer concordance for all items of the RS was fair to substantial in the case of Mayo score 0 [range 0. 35 'acute inflammatory cell infiltrate, crypt abscesses, mucin depletion and surface epithelial integrity'. Reader 2 showed similar results for 'crypt abscesses and surface epithelial integrity'. 
Discussion
This study documents poor concordance between 'daily practice' histological assessment of HR in UC biopsies by a general pathologist and expert reviews by GI-pathologists. This finding is important as our study mirrors daily practice where clinicians are struggling with the question whether to alter UC medication and the presence of HR may tip the balance in favour of a specific treatment strategy. We found strong correlations among expert GI-pathologists between the most frequently used histological activity scores for UC [RS and GS] and we observed a substantial inter-observer concordance for three histological scores [GS, HGI, RS], when re-evaluating UC biopsies assessed as HR by a general pathologist. Our study confirmed the reported excellent diagnostic properties of the most widely used UC histological disease activity indexes 24, 25 specifically for UC colonic biopsies with MH and limited histological inflammation.
The significant discrepancy we found between histological assessment of UC biopsies in daily practice and expert GI-pathologists is probably explained by bias and the need for expertise. The GI-pathologists from our research panel were blinded for both clinical and endoscopic data, whereas the initial assessor [in clinical practice] had full access to clinical and endoscopy results. It is conceivable that the clinical information available to the general pathologist influenced the conclusions of the histological evaluation. Secondly, routine histological assessment of IBD mucosal biopsies obtained from a colon with MH is complex and probably requires expertise that goes beyond routine clinical review. Indeed, some IBD studies have shown considerable inter-observer variability between pathologists. 30, 31 Histological inter-observer disagreement is by no means rare, nor is it limited to UC. In cancer treatment where results from pathology examinations are crucial, central pathology reading of biopsies taken in the context of trials is ubiquitous 32 and has made its way into daily oncology care. [33] [34] [35] This concept appears to have traction in IBD trials, 36 but is not yet in daily practice. We applaud the development of novel UC histological activity indexes [37] [38] [39] because we need accurate assessment of histological activity in both IBD trials and clinical practice. There are two other histological indexes for UC that merit discussion. Both the Nancy Index and the Robarts Histopathology Index [RHI] have shown good reproducibility, reliability and responsiveness, and underwent the most extensive validation of all existing histological activity indexes for UC. 37, 38, 40 The validation process for both indexes has been performed by expert pathologists, and both mainly use key items that are also present in existing scores such as GS, RS, HGI, Gramlich and GVS. These key items had high intra-and interobserver agreement and were subsequently included in the Nancy Index and RHI. Given the overlap of the included histological items [such as ulceration and acute inflammatory cell infiltrate], inclusion of either the Nancy Index or the RHI in our study would not change our key message. The real matter at stake, based on current study results, is the gap between the initial and expert histological assessment. Efforts to overcome this gap should be directed at dedicated learning pathways and/or central reading facilities. The Nancy Index might gain a future central role in these learning pathways because it is simple and easy to use. We found higher inter-observer concordance between expert GI-pathologists in the biopsies that were assessed by a general pathologist as histological inflamed compared to HR for all three histological activity scores. Similar results were found after categorization into endoscopic Mayo score 0 and 1, in favour of the Mayo 1 group. Both findings suggest that is it more complicated, even for specialized GI-pathologists, to reach an agreement in cases of minor histological inflammation. This assumption concurs with a study from the 1990s that investigated the reliability of the interpretation of IBD colonic biopsies by specialized GI-pathologists. True normal biopsies were frequently assessed as 'possible' or 'likely' 'non-specific inflammation' without agreement on this item. 30 In our study we found no correlation between the endoscopic Mayo score and any histological scores. In the case of Mayo 0 at endoscopy, we found histological activity in 20% [GS > 3.1] to 80% of cases [GS > 0.1] depending on the definition of HR used. In line with these results, a previous study described histological inflammation [GS ≥ 3.1] in 40% of cases with MH at endoscopy. 41 Unfortunately there is no unified definition of HR and the cutoff level of histological activity that is clinically relevant is still of debate. 15 Our study has several strengths and clinical implications. To mimic daily practice with regard to HR decision-making, we only used biopsies reported as endoscopic MH, and we involved expert GI-pathologists from both academic and non-academic hospitals.
For these histology analyses, we used blinded readers, which reduces the potential bias of taking the clinical condition of the patient into consideration. Most importantly, the described discrepancy between histological assessment of UC biopsies in daily practice and reassessment by dedicated GI-pathologists may have important implications in daily practice. Medical decision-making may increasingly depend on histological remission, and therefore it is important to realize and act upon this finding. There are some limitations of this study. First, the retrospective design of the study harbours the risk of bias. Secondly, the consensus meeting between GI-pathologists, before initiation of the study, may have caused bias by achieving a better inter-observer agreement. Third, we did not use central reading 42 for the endoscopic Mayo score, but used the Mayo score as reported by the endoscopist. In addition, the Mayo score has a variable interobserver concordance, [42] [43] [44] although this is likely to have little impact on the scope of this article.
In summary, the use of existing histological activity indexes evaluating UC colonic biopsies that were initially assessed as HR resulted in substantial inter-observer concordance. Of alarm is the observation that there was no correlation between the primary assessment of UC biopsies by the general pathologist and the reassessment by blinded expert GI-pathologists. This may have important implications for the selection process of a unified histological disease activity score in UC, and for the implementation of HR as a UC treatment target in daily practice.
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